Section 4: Clinical Pharmacy Services

4CPS-316

MULTIPLE SCLEROSIS OUTPATIENT PHARMACEUTICAL CARE BY AN IMPLANTED TELEPHARMACY TOOL DURING SARS-COV-2 PANDEMIC

4CPS-315

EVALUATION OF THE EFFECTIVENESS OF EARLY ADMINISTRATION OF TOCILIZUMAB IN PATIENTS WITH COVID-19

4CPS-314

3 DAY COURSE OF LOW DOSE SUBCUTANEOUS ANAKINRA IN PATIENTS WITH REFRACTORY MODERATE-SEVERE COVID-19: A PROOF-OF-CONCEPT STUDY

4CPS-313

EXPERIENCE OF THE USE OF BARICITINIB IN COVID-19 PNEUMONIA

4CPS-312

PHARMACEUTICAL INTERVENTIONS IN A NON-ONCOHAEMATOLOGICAL DAILY HOSPITAL

4CPS-311

REAL WORLD TOXICITY AND MANAGEMENT OF CHIMERIC ANTIGEN RECEPTOR T CELL THERAPIES TARGETING CD19 IN PATIENTS WITH HAEMATOLOGICAL MALIGNANCIES

4CPS-310

TOFACITINIB EFFECTIVENESS AND SAFETY RESULTS: REAL WORLD DATA

4CPS-309

BARRIERS TO ADHERENCE WITH PRESCRIBED TREATMENTS IN MULTIPLE SCLEROSIS PATIENTS

4CPS-308

EXPERIENCE WITH TERIFLUNOMIDE TREATMENT FOR MULTIPLE SCLEROSIS IN A UNIVERSITY HOSPITAL

4CPS-307

SAFETY EVALUATION OF NEW ANTIANDROGENIC DRUGS IN CASTRATION RESISTANT NON-METASTATIC PROSTATE CANCER

4CPS-306

DAROLUTAMIDE, ENZALUTAMIDE AND APALUTAMIDE: PLACE IN THERAPEUTICS OF CASTRATION RESISTANT NON METASTATIC PROSTATE CANCER

4CPS-305

EFFECTIVENESS AND SAFETY OF BRAF/MEK INHIBITORS IN ADVANCED OR METASTATIC MELANOMA IN TWO TERTIARY HOSPITALS

4CPS-304

RITUXIMAB AS AN ALTERNATIVE IN NEUROLOGIC DISORDERS: LONG TERM STUDY

4CPS-303

EFFICACY AND SAFETY OF MONOTHERAPY WITH PEMBROLIZUMAB IN NON-MICROCYTIC METASTATIC LUNG CANCER IN CLINICAL PRACTICE.

4CPS-302

SORAFENIB IN HEPATOCARCINOMA: RESULTS IN A REAL WORLD SETTING

Pages